If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
560.00    1.50 (0.27%)
Bid:
560.00
Ask:
560.50
Spread: 0.50 (0.089%)
Market Cap: £2.48b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Directorate Change

9 Feb 2022 07:00

RNS Number : 0742B
Tate & Lyle PLC
09 February 2022
 

Tate & Lyle PLC - 9 February 2022

 

Dawn Allen Appointed Chief Financial Officer of Tate & Lyle PLC

 

Tate & Lyle PLC (Tate & Lyle) is pleased to announce the appointment of Dawn Allen to the position of Chief Financial Officer, and to the Board of Tate & Lyle, with effect from 16 May 2022.

 

Dawn Allen joins Tate & Lyle from Mars, Incorporated where she has been Global CFO & VP, Global Transformation since 2020. Prior to that, during a 25-year career at Mars, she has held a number of senior financial roles in Europe and the US including Global Divisional CFO, Food, Drinks and Multisales and Regional CFO Wrigley Americas.

 

Nick Hampton, Chief Executive said: "I am delighted to welcome Dawn to Tate & Lyle. With over two decades of experience in the global food industry and a proven track record of financial leadership, Dawn is an outstanding addition to our executive team. I very much look forward to working with her and continuing to drive our growth agenda as Tate & Lyle enters a new chapter as a focused global food and beverage solutions business."

 

Gerry Murphy, Chairman said: "Dawn's extensive financial, commercial and international experience will be of great value to Tate & Lyle and she is a very welcome addition to our Board."

 

End

 

For more information contact Tate & Lyle PLC:

 

Christopher Marsh, VP Investor Relations

Tel: Mobile: +44 (0) 7796 192 688

 

Nick Hasell, FTI Consulting (Media)

Tel: Mobile: +44 (0) 7825 523 383

 

Notes:

 

1) Dawn Allen's Biography

 

Dawn Allen, 53, started her career in 1991 working for the auditing firm EY based in the UK. In 1995, she joined Courtaulds plc in their Corporate Finance department before moving to Mars, Incorporated in 1997 initially to work as Europe Confectionary Finance Manager spending some time based in the Netherlands. She returned to the UK in 2000 taking on Sales Finance and Financial Controller roles before being appointed as Country CFO Mars Chocolate UK in 2007.

 

In 2013 she moved to Chicago to act as Regional CFO Wrigley Americas before moving back to London in 2016 to take on the role of Global Divisional CFO, Food, Drinks and Multisales. Then, in 2020, she was appointed to her current position at Mars of Global CFO & VP, Global Transformation.

 

Dawn is also a Non-Executive Director of Tasty Bite Eatables Ltd, a public company based in India. She holds a Bachelor of Science in Chemistry at Bath University, UK, and is a member of the Institute of Chartered Accountants of England and Wales.

 

For rights free photos of Dawn Allen, please contact mediarelations@tateandlyle.com or call Esyllt Dafydd, Global Corporate PR Manager at Tate & Lyle on +44 (0)7775 544 136.

 

2) Remuneration Arrangements

 

Dawn Allen is appointed on an annual salary of £475,000. This will next be reviewed in April 2023. She will participate in our established executive director incentive arrangements, currently comprising, in summary:

 

· Annual discretionary bonus: 75% of salary at target and a maximum opportunity of 150% of salary, subject to performance conditions; with awards in excess of 100% of salary made as shares which are released after 24 months.

· Long-term (Performance Share Plan) awards of up to 300% (maximum) of base salary, subject to specified performance conditions over a three-year performance period, with shares subject to a further two-year post-vesting holding period.

 

She is required to accumulate a shareholding in Tate & Lyle equivalent to three times base salary within five years of joining.

 

To compensate Dawn for incentive awards that she will forfeit at Mars, Incorporated, Tate & Lyle will make her two performance-based Awards over Tate & Lyle shares: (i) an Award with a headline value of £785,000 which will be capable of vesting on the first anniversary of employment with Tate & Lyle, subject to achievement of performance conditions relating to specified individual and business objectives; and (ii) an Award with a headline value of £950,000, subject to the same performance conditions as Performance Share Plan Awards made to Executive Directors in 2021, and capable of vesting following the announcement of full year financial results for the year ending 31 March 2024. These compensatory awards will be subject to forfeiture/repayment in full if she ceases to be employed in the first 36 months of employment due to her resignation or dismissal for cause.

 

3) CFO Succession

 

Dawn Allen succeeds Vivid Sehgal as Tate & Lyle's Chief Financial Officer who, as announced on 3 November 2021, left the company on 31 December 2021.

 

4) Disclosures

 

Other than as disclosed above, no other information is required to be disclosed pursuant to paragraph 9.6.13R of the Listing Rules in respect of Dawn's appointment.

 

5) About Tate & Lyle

 

Tate & Lyle PLC is a leading global provider of food and beverage ingredients and solutions. Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.

 

Through our expertise in sweetening, mouthfeel and fibre fortification, our Food & Beverage Solutions business develops solutions which reduce sugar, calories and fat, add fibre, and provide texture and stability in categories including beverages, dairy, bakery, soups, sauces and dressings. Our Primary Products business produces nutritive sweeteners, industrial starches used in paper and packaging, acidulants and products used for animal nutrition.

 

We have around 4,400 employees working in more than 60 locations across 30 countries. Tate & Lyle's purpose is Improving Lives for Generations and through our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2021, Tate & Lyle sales totalled £2.8 billion. For more information, please visit https://www.tateandlyle.com or follow Tate & Lyle on Twitter, Linkedin or Facebook.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASSIFMAEESEIE
Date   Source Headline
20th Jun 20246:03 pmRNSTransaction in Own Shares
20th Jun 20247:05 amRNSLaunch of Share Buyback
20th Jun 20247:00 amRNSCombination of Tate & Lyle and CP Kelco
4th Jun 20245:22 pmRNSAnnual Financial Report and Notice of AGM
4th Jun 202411:00 amRNSDirector/PDMR Shareholding
3rd Jun 202412:00 pmRNSTotal Voting Rights
30th May 202412:15 pmRNSHolding(s) in Company
23rd May 20247:00 amRNSFinal Results
23rd May 20247:00 amRNSSale of remaining interest in Primient JV to KPS
20th May 20241:00 pmRNSDirectorate Change
17th May 20243:30 pmRNSHolding(s) in Company
14th May 20243:30 pmRNSHolding(s) in Company
13th May 202410:00 amRNSHolding(s) in Company
8th May 20243:15 pmRNSHolding(s) in Company
1st May 20242:30 pmRNSTotal Voting Rights
25th Apr 20243:45 pmRNSHolding(s) in Company
24th Apr 20247:00 amRNSDirectorate Change
22nd Apr 20242:30 pmRNSDirector/PDMR Shareholding
19th Apr 202410:15 amRNSHolding(s) in Company
17th Apr 20244:15 pmRNSHolding(s) in Company
17th Apr 202410:30 amRNSHolding(s) in Company
15th Apr 202410:30 amRNSHolding(s) in Company
10th Apr 20243:45 pmRNSHolding(s) in Company
8th Apr 202411:15 amRNSHolding(s) in Company
5th Apr 20243:45 pmRNSHolding(s) in Company
4th Apr 20244:15 pmRNSHolding(s) in Company
4th Apr 202412:30 pmRNSHolding(s) in Company
4th Apr 202411:30 amRNSDirector/PDMR Shareholding
2nd Apr 202412:45 pmRNSTotal Voting Rights
2nd Apr 202411:30 amRNSHolding(s) in Company
28th Mar 202411:45 amRNSHolding(s) in Company
25th Mar 202411:45 amRNSHolding(s) in Company
21st Mar 20244:10 pmRNSHolding(s) in Company
20th Mar 20243:00 pmRNSHolding(s) in Company
20th Mar 202412:00 pmRNSHolding(s) in Company
19th Mar 20242:00 pmRNSHolding(s) in Company
13th Mar 20244:00 pmRNSHolding(s) in Company
12th Mar 20244:24 pmRNSHolding(s) in Company
12th Mar 20244:22 pmRNSHolding(s) in Company
7th Mar 20247:00 amRNSDirectorate Change
4th Mar 20242:00 pmRNSDirector/PDMR Shareholding
4th Mar 20241:45 pmRNSHolding(s) in Company
28th Feb 20242:30 pmRNSHolding(s) in Company
21st Feb 20247:00 amRNSTrading Statement
1st Feb 202412:00 pmRNSTotal Voting Rights
11th Jan 20241:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202412:00 pmRNSBlock listing Interim Review
8th Dec 202311:45 amRNSDirector/PDMR Shareholding
6th Dec 202310:30 amRNSHolding(s) in Company
27th Nov 20234:15 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.